http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Akio Morita (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
-
Mayte Sánchez van Kammen,Jacoba P. Greving,Satoshi Kuroda,Daina Kashiwazaki,Akio Morita,Yoshiaki Shiokawa,Toshikazu Kimura,Christophe Cognard,Anne C. Januel,Antti Lindgren,Timo Koivisto,Juha E. Jääske 대한뇌졸중학회 2019 Journal of stroke Vol.21 No.3
Background and purpose Prediction of intracranial aneurysm growth risk can assist physicians in planning of follow-up imaging of conservatively managed unruptured intracranial aneurysms. We therefore aimed to externally validate the ELAPSS (Earlier subarachnoid hemorrhage, aneurysm Location, Age, Population, aneurysm Size and Shape) score for prediction of the risk of unruptured intracranial aneurysm growth. Methods From 11 international cohorts of patients ≥18 years with ≥1 unruptured intracranial aneurysm and ≥6 months of radiological follow-up, we collected data on the predictors of the ELAPSS score, and calculated 3- and 5-year absolute growth risks according to the score. Model performance was assessed in terms of calibration (predicted versus observed risk) and discrimination (c-statistic). Results We included 1,072 patients with a total of 1,452 aneurysms. During 4,268 aneurysm-years of follow-up, 199 (14%) aneurysms enlarged. Calibration was comparable to that of the followdevelopment cohort with the overall observed risks within the range of the expected risks. The c-statistic was 0.69 (95% confidence interval [CI], 0.64 to 0.73) at 3 years, compared to 0.72 (95% CI, 0.68 to 0.76) in the development cohort. At 5 years, the c-statistic was 0.68 (95% CI, 0.64 to 0.72), compared to 0.72 (95% CI, 0.68 to 0.75) in the development cohort. Conclusions The ELAPSS score showed accurate calibration for 3- and 5-year risks of aneurysm growth and modest discrimination in our external validation cohort. This indicates that the score is externally valid and could assist patients and physicians in predicting growth of unruptured intracranial aneurysms and plan follow-up imaging accordingly.
-
Preliminary Study of Needle Tracking in a Microsurgical Robotic System for Automated Operations
Yusuke Kurose,Young Min Baek,Yuya Kamei,Shinichi Tanaka,Kanako Harada,Shigeo Sora,Akio Morita,Naohiko Sugita,Mamoru Mitsuishi 제어로봇시스템학회 2013 제어로봇시스템학회 국제학술대회 논문집 Vol.2013 No.10
Surgical needle tracking is an important element of high-level automated operations conducted by surgical robotic systems. However, conventional needle tracking algorithms lack robust performancewith different needle postures and are not applicable to the small needles used during microsurgery. This paper discusses a robust, efficient needle tracking algorithm, which is capable of estimating all of the positions and of the postures of a microsurgical needle. In the preoperative preparation stage, contour models of the microsurgical needle are generated using a 3-D CAD model and saved in a database. During the operation, the system extracts the contours of the microsurgical needle from the microscopic image using the edge and the color information. The system then calculates the likelihood of the contour models in the database bymatching the contours extracted fromthemicroscopic image. The experimental results indicated that our proposed method has high accuracy when tracking a microsurgical needle, and that it performed robustly with different needle postures.
-
Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
Kim Kyongsong,Kyongsong Kim,Toyohiko Isu,Rinko Kokubo,Naotaka Iwamoto,Daijiro Morimoto,Masaaki Kawauchi,Akio Morita 대한척추외과학회 2021 Asian Spine Journal Vol.15 No.3
Study Design: Retrospective study. Purpose: This study aims to evaluate the effectiveness of mirogabalin in treatment of peripheral neuropathic pain due to lumbar spine disease. Overview of Literature: Mirogabalin is a novel selective ligand for the α2δ subunit of voltage-gated Ca channels. Methods: Between April and December 2019, we used mirogabalin to treat 60 consecutive patients (mean age, 67.6 years) with leg symptoms due to lumbar disease. The treatment outcome after 8 weeks of mirogabalin therapy was evaluated by comparing the pre- and post-administration Numerical Rating Scale (NRS) for leg symptoms and sleep disturbance, the NRS and Roland–Morris Disability Questionnaire for low back pain (LBP), and the quality of life (QOL) score (based on EuroQol five-dimension five-level scale). Results: Mirogabalin treatment was stopped at less than eight weeks in eight patients. The remaining 52 patients for evaluation were divided as group 1 (17 patients who presented with leg symptoms that lasted for less than 3 months) and group 2 (35 patients with leg symptoms that lasted longer than 3 months). The leg symptoms and LBP in both groups significantly improved at 4 and 8 weeks of treatment, and sleep disturbance and QOL were improved at 8 weeks as well. Compared to group 2, the pretreatment leg symptoms and QOL were significantly worse in group 1, and their improvement after 8 weeks of mirogabalin treatment was significantly better (p<0.05). Of the 60 original patients, 17 suffered adverse effects, which were mild in 16 patients and required treatment cessation due to excessive weight gain in one patient. Conclusions: We have validated the effect of mirogabalin on neuropathic pain due to lumbar spine disease, which has effectively addressed the associated leg symptoms, LBP, and sleep disturbance.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
